Nerve or Joint? Pain Speaks Two Languages | The Pained Brain, Chapter 20

Sudomotor test · Neuropathic pain

The Sudomotor Test in Mixed Pain: What It Adds and What It Cannot

A sudomotor test measures sweat-gland function driven by small autonomic nerve fibers in the hands and feet, an objective look at the small-fiber loss behind many kinds of neuropathic pain. It supports the examination-based grade; it does not locate a focal nerve lesion or name the pain generator.

Neuropathic pain is graded by examination, not detected by a single test. Objective small-fiber and autonomic measurement belongs beside that grade, as long as nobody expects it to name the generator.

Neuropathic pain inside a nociceptive diagnosis is common, under-named and treated in the wrong language. Among 473,815 US nursing home residents, coded neuropathic pain ran 14.6 percent, and 28.2 percent of those residents received no treatment for it at all. The sudomotor test is often proposed as the missing objective step, and it has a legitimate place, provided nobody asks it to name the generator. The chapter video, Nerve or Joint? Pain Speaks Two Languages, presents chapter 20 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. The graded evidence is in the book companion for chapter 20; the focus here is where objective small-fiber and autonomic measurement belongs in the workup.

How is neuropathic pain diagnosed?

The NeuPSIG grading system earns possible from a relevant lesion and a neuroanatomically plausible distribution, probable from sensory signs in that distribution, and definite from a confirmatory test; probable should usually be sufficient to initiate treatment, and negative signs outweigh positive ones. Uptake has been poor: only 56 of 220 clinical studies, 25 percent, used the system, and screening questionnaires are not to be used alone. At the bedside, a cluster of 8 history and examination items reached 72 percent sensitivity and 80 percent specificity for lumbosacral root compression.

The joint European assessment guideline gives a strong recommendation to DN4 and LANSS and to skin biopsy, a weak one to quantitative sensory testing, and supports neither functional neuroimaging nor nerve blocks for diagnosis. A diagnostic block still has a role in locating a generator for treatment planning; it simply does not grade neuropathic pain.

How often does nerve pain hide inside a joint or surgical diagnosis?

In hip osteoarthritis, 29 percent screened possible and 9 percent probable neuropathic-like on painDETECT. After thoracic surgery, persistent postoperative pain ran 38.1 percent across 19,001 patients, with a neuropathic component in 33.0 percent of those. Before knee arthroplasty in two cohorts of 524 patients, an unclear painDETECT band carried odds of 2.19 and a neuropathic-like band 2.83 for moderate-to-severe pain at a year; a Korean cohort of 148 using DN4 found no effect, with only about 22 neuropathic patients. Across a Swedish national registry of 6,579,612 adults, first-year pain medication use after a lower-limb nerve injury carried a relative risk of 5.60.

The social driver is the default pathway. A nociceptive label arrives with a nociceptive prescription and a procedural referral, and nobody is assigned to re-grade the pain when the response disappoints.

What does a sudomotor test measure?

Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service reporting to the ordering physician; it does not diagnose disease on its own and does not treat. Sudomotor testing measures sweat-gland function mediated by small autonomic fibers in the distal limbs, an objective window on the same small-fiber population whose loss drives many neuropathic phenotypes. Cardiac autonomic reflex tests and broader autonomic nervous system testing characterize cardiovagal and sympathetic function when the history suggests wider autonomic involvement.

Three limits should be stated once. First, none of these tests locates a focal lesion: a superior cluneal neuropathy, meralgia paresthetica or an infrapatellar saphenous branch injury will not declare itself on a distal sweat measurement. Second, Measura cannot diagnose a joint generator or exclude one; that remains examination and diagnostic injection. Third, small-fiber structure does not grade pain. Skin biopsy, the Level A confirmatory test and a different test done elsewhere, does not correlate with pain intensity, and intraepidermal density separated painful from painless diabetic neuropathy only at a standardized 0.31 across 664 patients. Read an abnormal sudomotor result as evidence of a substrate, not as a pain diagnosis.

What changes when a sudomotor test is abnormal?

Phenotype, then drug. Cluster analysis of 902 patients with peripheral neuropathic pain found sensory loss in 42 percent, thermal hyperalgesia in 33 percent and mechanical hyperalgesia in 24 percent. Oxcarbazepine’s number needed to treat was 3.9 in the irritable nociceptor phenotype against 13 without it, with a barely significant interaction; a phenotype-stratified lacosamide trial found no difference and closed early. In 30 patients with painful diabetic neuropathy, conditioned pain modulation correlated with duloxetine response at 0.628. Documented small-fiber loss moves a patient toward the neuropathic side of that ledger and toward the first-line agents built for it.

Metabolism, alongside. In recordings from people with diabetes, 79 percent of sampled C-fibers were pathologically altered, and 72 percent of nociceptors fired spontaneously in painful neuropathy against 15 percent in painless neuropathy. A small-fiber finding without laboratory panels for glycemia is half a result. Normative intraepidermal density also falls by 1.35 fibers per millimeter every five years, so age belongs in any interpretation.

Falls. Distal small-fiber and autonomic dysfunction belong in the same conversation as balance in older patients. Pair a positive result with the cognitive assessment and fall prevention workflow rather than filing it alone.

Who should get a sudomotor test?

Pain labeled as a joint or disc problem with burning quality, allodynia or a sensory deficit on examination.
Persistent pain after arthroplasty or thoracic surgery that has not responded to nociceptive treatment.
Patients with diabetes or a prediabetic A1c reporting distal burning or numbness.
Preoperative arthroplasty candidates in an unclear or neuropathic-like painDETECT band.

Selection criteria are summarized under who to test, and results support documentation in MIPS and quality reporting. The humility belongs here too: Dr. Padda has said he has treated a nerve in the language of a joint, as most of us have. The upstream error, choosing clinics and workups by the wrong measure, is taken up in comprehensive pain assessment. Patients can read the patient version.

Frequently asked questions

Does a sudomotor test diagnose small-fiber neuropathy?

It provides objective evidence about sweat-gland function mediated by small fibers, which supports the clinical picture, but it is not the Level A confirmatory standard; that is distal leg skin biopsy, done elsewhere. Interpret it with the examination, glycemic status and age. It does not grade pain severity or identify a focal lesion. Reading results in context is covered in interpreting the report.

Can objective testing distinguish neuropathic from nociceptive pain?

No validated test separates the two in a clinic. Imaging signatures classify patients against healthy controls rather than by mechanism, and structural small-fiber measures show only modest group differences between painful and painless neuropathy. The grade still comes from history and examination, and a diagnostic block locates a generator. Testing documents the substrate. The wider argument for measurement is in clinical rationale.

Should knee arthroplasty candidates be screened for neuropathic-like pain?

The larger evidence suggests value. Across two cohorts of 524 patients, a neuropathic-like painDETECT band before surgery carried odds of 2.83 for moderate-to-severe pain at one year and a lower Oxford Knee Score, while a smaller Korean cohort using DN4 did not replicate it. Screening before the date is booked sets expectations. Specialty use is outlined in specialty applications.

Which patients belong on a standing order for small-fiber and autonomic testing?

Reasonable candidates are patients with diabetes or prediabetes and distal burning, persistent postsurgical pain with neuropathic features, and pain carrying a joint or disc label that has not responded to nociceptive treatment. A standing order keeps the decision out of a crowded visit and pairs the test with glycemic labs. Templates are described in standing orders for screening.

How should results be documented?

File them as structured data with the examination findings and the neuropathic pain grade, so the substrate stays visible when later procedure and medication notes are written. Record glycemic status and age beside any small-fiber result, since both change interpretation, and repeat measurement shows the direction of travel. The mechanics are in getting results into the record.

What is the best test for small-fiber neuropathy?

The confirmatory Level A test is a skin biopsy from the lower leg, done elsewhere. A sudomotor test is an objective, noninvasive look at the same small-fiber population through sweat-gland function, and it supports the clinical picture. Neither one grades pain. The neuropathic pain grade still comes from the history and a hands-on examination.

Can a sudomotor test find a pinched or injured nerve?

No. A sudomotor test reads sweat-gland function in the hands and feet, so a single injured nerve elsewhere will not show up on it. A superior cluneal neuropathy, meralgia paresthetica or an injured saphenous branch below the knee needs an examination and, where indicated, a diagnostic injection. The test also cannot diagnose or exclude a painful joint.

Does age change how a small-fiber result is read?

Yes. Normal small-fiber density in the skin falls by 1.35 fibers per millimeter every five years, so the same reading means something different at different ages. Age and blood sugar status belong beside any small-fiber or sudomotor result, and repeat measurement shows the direction of travel better than a single reading.

Add objective small-fiber data to the pain workup

Learn how the Measura protocol pairs sudomotor, autonomic and metabolic testing with the neuropathic pain workup, with results returned to the ordering physician.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Mbrah, A. K., Nunes, A. P., Hume, A. L., Zhao, D., Jesdale, B. M., Bova, C., & Lapane, K. L. (2022). Prevalence and treatment of neuropathic pain diagnoses among U.S. nursing home residents. Pain, 163(7), 1370-1377. https://doi.org/10.1097/j.pain.0000000000002525
Finnerup, N. B., Haroutounian, S., Kamerman, P., Baron, R., Bennett, D. L. H., Bouhassira, D., Cruccu, G., Freeman, R., Hansson, P., Nurmikko, T., Raja, S. N., Rice, A. S. C., Serra, J., Smith, B. H., Treede, R. D., & Jensen, T. S. (2016). Neuropathic pain: an updated grading system for research and clinical practice. Pain, 157(8), 1599–1606. https://doi.org/10.1097/j.pain.0000000000000492
Truini, A., Aleksovska, K., Anderson, C. C., Attal, N., Baron, R., Bennett, D. L., Bouhassira, D., Cruccu, G., Eisenberg, E., Enax-Krumova, E., Davis, K. D., Di Stefano, G., Finnerup, N. B., Garcia-Larrea, L., Hanafi, I., Haroutounian, S., Karlsson, P., Rakusa, M., Rice, A. S. C., … Veluchamy, A. (2023). Joint European Academy of Neurology-European Pain Federation-Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment. European Journal of Neurology, 30(8), 2177-2196. https://doi.org/10.1111/ene.15831
Mistry, J., Heneghan, N. R., Noblet, T., Falla, D., & Rushton, A. (2020). Diagnostic utility of patient history, clinical examination and screening tool data to identify neuropathic pain in low back related leg pain: a systematic review and narrative synthesis. BMC Musculoskeletal Disorders, 21(1), 532. https://doi.org/10.1186/s12891-020-03436-6
Wall, A. J. W., Leyland, K. M., Kiran, A., Arden, N. K., Cooper, C., Wanigasekera, V., Javaid, M. K., Price, A. J., Tracey, I. M. C., & Irani, A. (2025). PainDETECT as a Potential Tool for Personalized Medicine: Predicting Outcome One Year After Knee Arthroplasty. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 9(5), 100649. https://doi.org/10.1016/j.mayocpiqo.2025.100649
Lauria, G., Hsieh, S. T., Johansson, O., Kennedy, W. R., Leger, J. M., Mellgren, S. I., Nolano, M., Merkies, I. S. J., Polydefkis, M., Smith, A. G., Sommer, C., & Valls-Solé, J. (2010). European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Journal of Neurology, 17(7), 903-912, e44-e49. https://doi.org/10.1111/j.1468-1331.2010.03023.x
Gad, H. Y., Devigili, G., Merkies, I., Gilron, I., MacDonald, R., Lauria, G., & Malik, R. A. (2026). Corneal confocal microscopy and skin biopsy to differentiate painful from painless diabetic neuropathy: A systematic review with multiple meta-analyses. European Journal of Neurology, 33(3), e70576. https://doi.org/10.1111/ene.70576
Baron, R., Maier, C., Attal, N., Binder, A., Bouhassira, D., Cruccu, G., Finnerup, N. B., Haanpää, M., Hansson, P., Hüllemann, P., Jensen, T. S., Freynhagen, R., Kennedy, J. D., Magerl, W., Mainka, T., Reimer, M., Rice, A. S. C., Segerdahl, M., Serra, J., … Treede, R. D. (2017). Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain, 158(2), 261–272. https://doi.org/10.1097/j.pain.0000000000000753
Demant, D. T., Lund, K., Vollert, J., Maier, C., Segerdahl, M., Finnerup, N. B., Jensen, T. S., & Sindrup, S. H. (2014). The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study. Pain, 155(11), 2263–2273. https://doi.org/10.1016/j.pain.2014.08.014
Becker, A. K., Babes, A., Düll, M. M., Khalil, M., Kender, Z., Gröner, J., Namer, B., Reeh, P. W., & Sauer, S. K. (2023). Spontaneous activity of specific C-nociceptor subtypes from diabetic patients and mice: Involvement of reactive dicarbonyl compounds and (sensitized) transient receptor potential channel A1. Journal of the Peripheral Nervous System, 28(2), 202–225. https://doi.org/10.1111/jns.12546